- Home
- CNTX vs ACHV Comparison
CNTX vs ACHV Comparison
Compare CNTX & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- ACHV
- Stock Information
- Founded
- CNTX 2015
- ACHV N/A
- Country
- CNTX United States
- ACHV Canada
- Employees
- CNTX N/A
- ACHV N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CNTX Health Care
- ACHV Health Care
- Exchange
- CNTX Nasdaq
- ACHV Nasdaq
- Market Cap
- CNTX 78.0M
- ACHV 72.5M
- IPO Year
- CNTX 2021
- ACHV N/A
- Fundamental
- Price
- CNTX $0.58
- ACHV $3.59
- Analyst Decision
- CNTX Strong Buy
- ACHV Strong Buy
- Analyst Count
- CNTX 4
- ACHV 3
- Target Price
- CNTX $6.00
- ACHV $14.33
- AVG Volume (30 Days)
- CNTX 164.6K
- ACHV 234.9K
- Earning Date
- CNTX 05-07-2025
- ACHV 05-13-2025
- Dividend Yield
- CNTX N/A
- ACHV N/A
- EPS Growth
- CNTX N/A
- ACHV N/A
- EPS
- CNTX N/A
- ACHV N/A
- Revenue
- CNTX N/A
- ACHV N/A
- Revenue This Year
- CNTX N/A
- ACHV N/A
- Revenue Next Year
- CNTX N/A
- ACHV N/A
- P/E Ratio
- CNTX N/A
- ACHV N/A
- Revenue Growth
- CNTX N/A
- ACHV N/A
- 52 Week Low
- CNTX $0.49
- ACHV $1.84
- 52 Week High
- CNTX $2.75
- ACHV $5.58
- Technical
- Relative Strength Index (RSI)
- CNTX 33.91
- ACHV 70.30
- Support Level
- CNTX $0.49
- ACHV $2.89
- Resistance Level
- CNTX $0.71
- ACHV $3.32
- Average True Range (ATR)
- CNTX 0.08
- ACHV 0.25
- MACD
- CNTX -0.02
- ACHV 0.07
- Stochastic Oscillator
- CNTX 33.31
- ACHV 91.47
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.